NCT07038356View on ClinicalTrials.gov

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

536

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Decompensated Heart Failure (ADHF)
Interventions
DRUG

Empagliflozin 10 MG Oral Tablet [Jardiance]

Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

DRUG

Placebo

Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

All Listed Sponsors
lead

Christian Schulze

OTHER